Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9259573 | 0.81 | MAPT (0.38) | MAPTACEDPP4POLBPIK3CD | |
| SCHEMBL9252361 | 0.76 | PIK3CD (0.38) | MAPTACEDPP4POLBPIK3CD | |
| SCHEMBL18067762 | 0.75 | PIK3CD (0.37) | MAPTACEDPP4POLBPIK3CD | |
| SCHEMBL18067760 | 0.75 | PIK3CD (0.37) | MAPTACEDPP4POLBPIK3CD | |
| SCHEMBL9252755 | 0.75 | PIK3CD (0.37) | MAPTACEDPP4POLBPIK3CD | |
| SCHEMBL2602295 | 0.74 | DPP4 (0.36) | MAPTACEDPP4POLBPIK3CD | |
| SCHEMBL9252445 | 0.72 | PIK3CD (0.35) | MAPTACEDPP4PIK3CD | |
| SCHEMBL30428415 | 0.70 | BACE1 (0.35) | MAPTACEDPP4PIK3CD | |
| SCHEMBL9252408 | 0.70 | ACE (0.39) | MAPTACEDPP4PIK3CD | |
| SCHEMBL9255859 | 0.70 | CTSV (0.35) | MAPTACEDPP4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | MAPT 53/4885ACE 307/4885SMN1; SMN2 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.